Privium Fund Management B.V. Increases Stake in Axsome Therapeutics, Inc. $AXSM

Privium Fund Management B.V. grew its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 7.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,878 shares of the company’s stock after acquiring an additional 4,146 shares during the quarter. Axsome Therapeutics comprises about 1.9% of Privium Fund Management B.V.’s portfolio, making the stock its 17th largest position. Privium Fund Management B.V. owned 0.11% of Axsome Therapeutics worth $10,388,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc raised its stake in shares of Axsome Therapeutics by 20,300.0% in the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after acquiring an additional 203 shares during the period. First Horizon Corp purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at $34,000. Optiver Holding B.V. raised its stake in shares of Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the period. Essex Investment Management Co. LLC purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at $38,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at $40,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Down 0.3%

NASDAQ AXSM opened at $223.06 on Wednesday. The company’s 50-day moving average price is $171.73 and its 200-day moving average price is $163.34. The company has a current ratio of 1.55, a quick ratio of 1.48 and a debt-to-equity ratio of 1.38. The stock has a market cap of $11.47 billion, a PE ratio of -59.80 and a beta of 0.59. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $234.29.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The company had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 246.90% and a negative net margin of 26.59%.The business’s revenue was up 57.4% compared to the same quarter last year. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -1.05 earnings per share for the current year.

Insider Transactions at Axsome Therapeutics

In other news, insider Ari Maizel sold 7,500 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares in the company, valued at approximately $1,368,150. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mark Coleman sold 25,000 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.11, for a total transaction of $4,027,750.00. Following the completion of the transaction, the director owned 47,140 shares in the company, valued at approximately $7,594,725.40. The trade was a 34.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 72,628 shares of company stock worth $12,205,662. Insiders own 20.60% of the company’s stock.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AXSM. Royal Bank Of Canada increased their target price on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research note on Tuesday. HC Wainwright set a $290.00 target price on shares of Axsome Therapeutics in a research note on Tuesday. Robert W. Baird increased their target price on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research note on Tuesday. Leerink Partners increased their target price on shares of Axsome Therapeutics from $150.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, January 28th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $272.00 price target on shares of Axsome Therapeutics in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $251.89.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.